Assessment Scales for Progressive Supranuclear Palsy
The Progressive Supranuclear Palsy Rating Scale (PSPRS) is the most established and validated clinical assessment tool for evaluating PSP, comprising 28 items across six domains with scores ranging from 0-100. 1
Primary Assessment Scale: PSPRS
The original PSPRS remains the gold standard for PSP assessment, covering:
- Daily activities (by history)
- Behavior
- Bulbar function
- Ocular motor function
- Limb motor function
- Gait and midline function
The scale demonstrates excellent inter-rater reliability (intraclass correlation coefficient 0.86) and is a strong independent predictor of survival (P < 0.0001). 1 Mean progression rate is 11.3 ± 11.0 points per year, making it sensitive to disease progression over time.
Modified Versions for Specific Applications
For Telemedicine/Remote Assessment
Use the modified PSPRS-21 (21-item version), which removes items requiring physical examination while maintaining excellent agreement with the original scale. 2 This version:
- Excludes neck rigidity, limb rigidity, postural stability, three ocular motor items, and limb dystonia
- Shows 0.94 agreement with original PSPRS at baseline
- Maintains 0.92-0.95 agreement for measuring change over 6-12 months
- Remains highly predictive of survival
For Clinical Trials
The FDA has proposed a 10-item subscale as an alternative to full PSPRS for interventional trials. 3 However, a 14-item modified PSPRS focusing on clinically meaningful disease milestones offers comparable power for detecting treatment effects while emphasizing functional relevance. 4 This version:
- Retains only items capturing severe disease milestones
- Each item scores 0-2 points
- Requires n=41 per arm to detect 50% slowing at 12 months (80% power)
Alternative Rapid Assessment Tool
The Progressive Supranuclear Palsy Clinical Deficits Scale (PSP-CDS) provides a rapid 4-minute assessment covering seven domains, each scored 0-3. 5 This scale:
- Covers: Akinesia-rigidity, Bradyphrenia, Communication, Dysphagia, Eye movements, Finger dexterity, and Gait & balance
- Correlates strongly with PSPRS (R = 0.88, P < 0.001)
- Shows excellent inter-rater reliability (0.96) and test-retest stability (0.99)
- Requires only 65 patients per arm for 1-year therapeutic trials to detect 50% change in progression
Clinical Application Algorithm
For routine clinical monitoring: Use the full 28-item PSPRS for comprehensive assessment and prognostication. A score of 40-49 indicates 3-year survival of only 41.9% and 1-year gait retention of 51.7%. 1
For telemedicine visits: Use the mPSPRS-21, which maintains validity without requiring physical examination items. 2
For rapid screening or frequent monitoring: Use the PSP-CDS, which takes only 4 minutes and captures clinically meaningful deficits across all PSP phenotypes. 5
For clinical trial endpoints: Consider the Combined Assessment of Function and Survival (CAFS), which integrates PSPRS scores with survival data to account for nonrandom missingness due to death in 12-24 month trials. 6
Important Caveats
The PSPRS was developed primarily for Richardson's syndrome (PSP-RS), the classic phenotype. All these scales demonstrate validity across the broader spectrum of PSP phenotypes including PSP-parkinsonism, PSP-progressive gait freezing, and PSP-corticobasal syndrome. 5, 7
Neither onset age nor gender correlates well with rate of progression, so these factors should not influence scale interpretation. 1 The scales measure disease severity and progression but do not replace the need for applying MDS-PSP diagnostic criteria for accurate phenotype classification. 7